New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
07:26 EDTOCR, SIAL, REGN, MRK, BDX, ABBV, WPIGoldman to host a conference
Healthcare CEOs Unscripted Conference is being held in New York on January 3.
News For REGN;WPI;BDX;SIAL;ABBV;MRK;OCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 19, 2015
07:28 EDTMRKUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link
06:55 EDTMRKGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
06:26 EDTSIALMerck KGaA sees wrapping Sigma-Aldrich deal mid-year, Reuters reports
Subscribe for More Information
May 18, 2015
12:34 EDTREGNRegeneron, Sanofi announce positive pivotal Phase 2b dupilumab data in asthma
Subscribe for More Information
May 15, 2015
16:46 EDTABBVAbbVie extends exchange offer to acquire Pharmacyclics
AbbVie (ABBV) announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics (PCYC) to 5 p.m., New York City time, on May 22. The depositary of the exchange offer has advised that, as of 4:00 p.m., New York City time, on May 15, a total of approximately 42,822,941 shares of Pharmacyclics common stock were validly tendered and not properly withdrawn in the exchange offer. All other terms and conditions of the exchange offer remain unchanged.
10:29 EDTABBVAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:45 EDTABBVAbbVie reports FDA orphan designation for Humira in treatment of HS
Subscribe for More Information
08:15 EDTREGNRegeneron target upped to $550 at Credit Suisse citing growth potential
Subscribe for More Information
08:04 EDTREGNRegeneron price target raised to $450 from $427 at JPMorgan
JPMorgan said it is "increasingly confident" in dupilumab's longer-term prospects in asthma ahead of the full Phase 2b results. The firm believes the drug's peak sales could top $4B. JPMorgan keeps a Neutral rating on Regeneron, however, saying its valuation already reflects blockbuster sales for Eylea, Praluent, sarilumab and dupilumab. It raised its price target for the name to $450 from $427.
May 14, 2015
13:12 EDTABBVAbbVie granted orphan status for Humira
Subscribe for More Information
10:41 EDTABBVAnalysts upbeat on Amgen's Kyprolis after ASCO abstracts
Subscribe for More Information
09:22 EDTMRKLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:09 EDTABBVBristol-Myers down 1.3% after release of ASCO abstracts
Subscribe for More Information
May 13, 2015
18:33 EDTMRKMerck to present new Keytruda data on 10 types of cancer at 2015 ASCO meeting
Subscribe for More Information
13:12 EDTMRK, ABBVSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information
08:07 EDTBDXBecton Dickinson receives FDA clearance for insulin infusion set
Subscribe for More Information
May 12, 2015
13:13 EDTMRKExpert says Norway biosimilar case an 'outlier,' CT Financial News reports
Subscribe for More Information
07:09 EDTSIALSigma-Aldrich expands facility in Carlsbad
Sigma-Aldrich Corporation custom manufacturing business unit, SAFC Commercial, announced the strategic expansion of its existing facility in Carlsbad, Calif. The investment will further enable SAFC to offer clinical and commercial bulk drug production, as well as fill/finish of viral products for its gene therapy, viral vaccine and immunotherapy customers.
07:08 EDTSIALSigma-Aldrich business completes expansion of St. Louis facility
Sigma-Aldrich announced that SAFC Commercial, its custom manufacturing services business unit, has completed the expansion of its St. Louis facility to support commercial-scale antibody drug conjugate manufacturing. The facility is in final validation and expected to go online as planned in the third quarter of 2015. Once validated, customers will benefit from working with a single supplier from discovery to commercialization.
06:09 EDTMRKThreshold announces Merck receives FDA Fast Track designation for evofosfamide
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use